Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
• Older patients with T2DM are often excluded from randomized controlled trials. • The insulin-independent mechanism of action makes SGLT2i suitable in the elderly. • Our study focused on SGLT2i-treated older patients with T2DM, stratified by age (65–69 and ≥70 years). • HbA1c reduction, eGFR variat...
| Veröffentlicht in: | A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients. - 2016. - Amsterdam [u.a.] |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2021
|
| Zugriff auf das übergeordnete Werk: | A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients |
| Schlagworte: | Type 2 diabetes Elderly Sodium-glucose cotransporter 2 inhibitors Real-world evidence |
| Umfang: | 6 |
| Zusammenfassung: | • Older patients with T2DM are often excluded from randomized controlled trials. • The insulin-independent mechanism of action makes SGLT2i suitable in the elderly. • Our study focused on SGLT2i-treated older patients with T2DM, stratified by age (65–69 and ≥70 years). • HbA1c reduction, eGFR variation and tolerability were similar across age groups. • Among elderly T2DM individuals, SGLT2i are effective, safe and fairly well tolerated. |
|---|---|
| Beschreibung: | 6 |
| DOI: | 10.1016/j.pcd.2020.10.002 |